Kv7 PLATFORM

Reshaping the course
of young lives.

Epilepsy is one of the world’s most common diseases. A rare form of epilepsy in newborns, with frequent seizures beginning in the first days or hours of life, is called KCNQ2 epileptic encephalopathy (KCNQ2-EE).

Our platform is creating hope that investigational Kv7 drugs may control seizures and improve or normalize brain development in children.

 
 
Knopp_fallbackimage_home.jpg
 
 

WHAT WE DO

Creating new treatments.
Changing human health.

Knopp Biosciences strives to advance the treatment of devastating immunological and neurological diseases by discovering, developing, and delivering breakthrough medicines.

 
 
121119_1092_crop.jpg
 
 
 

Promising discoveries.

Knopp’s pipeline spans preclinical discovery to Phase 2 in immunological and neurological diseases.

 
 
 
121119_0622_white.jpg
 

Two areas of focus.

neurology.jpg

Neurological diseases

We are pursuing novel agents to activate a key ion channel in nerve cells, targeting a devastating genetic mutation associated with epileptic encephalopathy, as well as other epilepsies and neuropathic pain.

Learn More →

wbc.jpg

Immunological conditions

Knopp is advancing the development of dexpramipexole as an anti-inflammatory therapeutic based on extensive preclinical and clinical evidence of its activity in modulating white blood cells known as eosinophils.

Learn More →

 
 

In the News

 
 
bgcolor.jpg